Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients

Learn more about:
Related Clinical Trial
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease rTMS in Wilmson Diasease Dysarthria Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients

Official Title

Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients

Brief Summary

      Generalized epilepsy is rarely reported in patients with Wilson disease (WD) and lacks
      experience in clinical practice. We aim to provide better experience for the diagnosis and
      treatment for WD patients with epilepsy in the future.
    

Detailed Description

      A retrospective study was performed in 13 Chinese WD patients with generalized epilepsy. Each
      patient was diagnosed with WD by clinical evaluation and genetic screening. Patients were
      given small doses of antiepileptic drugs (AEDs), followed by copper-chelation therapy when
      the seizures stabilized. Clinical manifestations, brain imaging changes, and treatment and
      outcome after a long-term follow-up were analyzed.
    


Study Type

Observational


Primary Outcome

Number of participants with treatment stop seizures attacks

Secondary Outcome

 Number of participants with treatment have improved brain MRI

Condition

Wilson Disease

Intervention

genetic test

Study Arms / Comparison Groups

 WD-seizures
Description:  Chinese WD patients with generalized epilepsy

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Genetic

Estimated Enrollment

13

Start Date

September 1, 2010

Completion Date

March 1, 2019

Primary Completion Date

September 1, 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Each patient was diagnosed with WD by clinical evaluation and genetic screening and
             had ever experienced generalized epilepsy

        Exclusion Criteria:

          -  Not WD & without generalized epilepsy
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT04965571

Organization ID

WD-seizures


Responsible Party

Sponsor

Study Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University


Study Sponsor

, , 


Verification Date

July 2021